The Competition Commission of India (CCI) has dismissed a complaint against Cipla and the Bengal Chemist and Druggists Association (BCDA) over alleged non-supply of medicines.
While dismissing the complaint, the fair-trade regulator said the complainant tried to give a commercial dispute between him and Cipla a colour of competition issue. The complainant had alleged that despite placement of repeated orders, Cipla had stopped the supply of medicines at the behest of BCDA.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.45 |
| Dr. Reddys Lab | 1235.10 |
| Cipla | 1233.00 |
| Zydus Lifesciences | 939.95 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: